Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 2/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.31 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.31 |
| ▸ | TUBB | P07437 | 1/20 | 0.31 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.31 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.31 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.31 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.31 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.31 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.31 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.31 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.31 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.31 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.31 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.31 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.31 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873747 | 1.00 | EZH2 (0.32) | EZH2PDGFRBTLK2TUBB4ATUBB | |
| SCHEMBL13922099 | 0.82 | BCL2L1 (0.40) | PDGFRB | |
| SCHEMBL3872980 | 0.82 | BCL2L1 (0.40) | PDGFRB | |
| SCHEMBL14612872 | 0.80 | ALDH1A1 (0.38) | TLK2 | |
| SCHEMBL3879270 | 0.77 | — | — | |
| SCHEMBL3879273 | 0.77 | — | — | |
| SCHEMBL7216095 | 0.77 | — | — | |
| SCHEMBL7216100 | 0.77 | — | — | |
| SCHEMBL3874519 | 0.77 | — | — | |
| SCHEMBL3877410 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1431286-A2 | Prodigiosin derivatives for treating cancer or viral diseases | Gemin X Biotechnologies Inc. (CA) | 2004-06-23 | — | — | EP | claimed |
| US-20030009032-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2003-01-09 | — | — | US | claimed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-3027754-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | enEvolv, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017866-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-7491745-B2 | Pyrrole-Type compounds, compositions and methods for treating cancer or viral disease | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-20070037856-A1 | e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2007-02-15 | — | — | US | disclosed |
| EP-1431286-A2 | Prodigiosin derivatives for treating cancer or viral diseases | Gemin X Biotechnologies Inc. (CA) | 2004-06-23 | — | — | EP | disclosed |
| EP-1255753-B1 | PRODIGIOSIN-DERIVATIVES AS NEOPLASTIC AND ANTI-VIRAL AGENTS | GEMIN X BIOTECHNOLOGIES INC (CA) | 2004-06-23 | — | — | EP | disclosed |
| US-20040014987-A1 | Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X BIOTECHNOLOGIES INC. | 2004-01-22 | — | — | US | disclosed |
| US-6602879-B2 | For inhibiting the replication or infectivity of a virus; therapy | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2003-08-05 | — | — | US | disclosed |
| US-20030009032-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2003-01-09 | — | — | US | disclosed |
| US-6407244-B1 | ANTIPROLIFERATIVE AGENT | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014987-A1 | Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases | POLI, PYCR1, ZC3HAV1 | EZH2 1216/4885PDGFRB 3161/4885TLK2 4363/4885 |
| US-20030009032-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | POLI, PYCR1, ZC3HAV1 | EZH2 1216/4885PDGFRB 3161/4885TLK2 4363/4885 |
| US-20070037856-A1 | e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide | POLI, PCNA, ELL | EZH2 806/4885PDGFRB 2455/4885TLK2 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.